- Home
- AKBA vs FIGS Comparison
AKBA vs FIGS Comparison
Compare AKBA & FIGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- FIGS
- Stock Information
- Founded
- AKBA 2007
- FIGS 2013
- Country
- AKBA United States
- FIGS United States
- Employees
- AKBA N/A
- FIGS N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- FIGS Apparel
- Sector
- AKBA Health Care
- FIGS Consumer Discretionary
- Exchange
- AKBA Nasdaq
- FIGS Nasdaq
- Market Cap
- AKBA 861.7M
- FIGS 853.4M
- IPO Year
- AKBA 2014
- FIGS 2021
- Fundamental
- Price
- AKBA $3.04
- FIGS $7.08
- Analyst Decision
- AKBA Strong Buy
- FIGS Sell
- Analyst Count
- AKBA 5
- FIGS 4
- Target Price
- AKBA $6.90
- FIGS $5.38
- AVG Volume (30 Days)
- AKBA 4.0M
- FIGS 2.1M
- Earning Date
- AKBA 08-07-2025
- FIGS 08-07-2025
- Dividend Yield
- AKBA N/A
- FIGS N/A
- EPS Growth
- AKBA N/A
- FIGS N/A
- EPS
- AKBA N/A
- FIGS 0.04
- Revenue
- AKBA $203,733,000.00
- FIGS $569,581,000.00
- Revenue This Year
- AKBA $27.95
- FIGS $1.05
- Revenue Next Year
- AKBA $43.88
- FIGS $3.16
- P/E Ratio
- AKBA N/A
- FIGS $163.18
- Revenue Growth
- AKBA 16.75
- FIGS 3.41
- 52 Week Low
- AKBA $1.24
- FIGS $3.57
- 52 Week High
- AKBA $4.08
- FIGS $7.31
- Technical
- Relative Strength Index (RSI)
- AKBA 34.84
- FIGS 67.89
- Support Level
- AKBA $2.92
- FIGS $6.07
- Resistance Level
- AKBA $3.44
- FIGS $7.05
- Average True Range (ATR)
- AKBA 0.15
- FIGS 0.32
- MACD
- AKBA -0.06
- FIGS 0.04
- Stochastic Oscillator
- AKBA 13.79
- FIGS 81.53
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.